JP2014502972A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502972A5 JP2014502972A5 JP2013548605A JP2013548605A JP2014502972A5 JP 2014502972 A5 JP2014502972 A5 JP 2014502972A5 JP 2013548605 A JP2013548605 A JP 2013548605A JP 2013548605 A JP2013548605 A JP 2013548605A JP 2014502972 A5 JP2014502972 A5 JP 2014502972A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- trypsin
- oxycodone
- compound
- trypsin inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940002612 prodrug Drugs 0.000 claims 37
- 239000000651 prodrug Substances 0.000 claims 37
- 239000002753 trypsin inhibitor Substances 0.000 claims 31
- 229940122618 Trypsin inhibitor Drugs 0.000 claims 29
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 29
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 26
- 229960002085 oxycodone Drugs 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 22
- 102000004142 Trypsin Human genes 0.000 claims 18
- 108090000631 Trypsin Proteins 0.000 claims 18
- 239000012588 trypsin Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 10
- 238000006243 chemical reaction Methods 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 150000002085 enols Chemical class 0.000 claims 5
- 230000037406 food intake Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000001301 oxygen Substances 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 230000003278 mimic effect Effects 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- -1 amino, substituted amino, hydroxyl Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical group CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 239000004202 carbamide Chemical group 0.000 claims 2
- 235000013877 carbamide Nutrition 0.000 claims 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical group CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 238000013160 medical therapy Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- SXNCILYLEKIXPV-IZZNHLLZSA-N (4s)-4-[[(2r)-2-(benzylsulfonylamino)-4-phenylbutanoyl]amino]-5-[(4-carbamimidoylphenyl)methylamino]-5-oxopentanoic acid Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](NS(=O)(=O)CC=1C=CC=CC=1)CCC1=CC=CC=C1 SXNCILYLEKIXPV-IZZNHLLZSA-N 0.000 claims 1
- WPANETAWYGDRLL-UHFFFAOYSA-N 4-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(N)C=C1 WPANETAWYGDRLL-UHFFFAOYSA-N 0.000 claims 1
- LPRSIBLBCFRSKX-QFIPXVFZSA-N 6-[4-[(2s)-5-(diaminomethylideneamino)-2-(naphthalen-2-ylsulfonylamino)pentanoyl]piperazin-1-yl]-6-oxohexanoic acid Chemical compound O=C([C@@H](NS(=O)(=O)C=1C=C2C=CC=CC2=CC=1)CCCNC(=N)N)N1CCN(C(=O)CCCCC(O)=O)CC1 LPRSIBLBCFRSKX-QFIPXVFZSA-N 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- ZXBYWYQEQQBMBT-UHFFFAOYSA-N amido phenyl pyruvic acid Chemical compound NC(=N)C1=CC=C(CC(=O)C(O)=O)C=C1 ZXBYWYQEQQBMBT-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000010228 ex vivo assay Methods 0.000 claims 1
- 238000005462 in vivo assay Methods 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- YVTDJCBGKCQSPF-DFIMAEIUSA-N CC(C)(CNC([C@H](CCCNC(N)=N)NC(CNC(CC(O)=O)=O)=O)=O)CN(C)C(OC([C@@H]([C@]12CCN(C)[C@@H]3C4)Oc5c1c4ccc5OC)=CC[C@]23O)=O Chemical compound CC(C)(CNC([C@H](CCCNC(N)=N)NC(CNC(CC(O)=O)=O)=O)=O)CN(C)C(OC([C@@H]([C@]12CCN(C)[C@@H]3C4)Oc5c1c4ccc5OC)=CC[C@]23O)=O YVTDJCBGKCQSPF-DFIMAEIUSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431781P | 2011-01-11 | 2011-01-11 | |
| US61/431,781 | 2011-01-11 | ||
| PCT/US2012/020649 WO2012096887A2 (en) | 2011-01-11 | 2012-01-09 | Compositions comprising enzyme-cleavable oxycodone prodrug |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502972A JP2014502972A (ja) | 2014-02-06 |
| JP2014502972A5 true JP2014502972A5 (enExample) | 2015-06-18 |
| JP6016810B2 JP6016810B2 (ja) | 2016-10-26 |
Family
ID=46455749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013548605A Active JP6016810B2 (ja) | 2011-01-11 | 2012-01-09 | 酵素切断可能なオキシコドンプロドラッグを含んでなる組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8569228B2 (enExample) |
| EP (1) | EP2663187B1 (enExample) |
| JP (1) | JP6016810B2 (enExample) |
| CN (1) | CN103384472B (enExample) |
| AU (1) | AU2012205733B2 (enExample) |
| BR (1) | BR112013017296B1 (enExample) |
| CA (1) | CA2814763C (enExample) |
| DK (1) | DK2663187T3 (enExample) |
| ES (1) | ES2584634T3 (enExample) |
| IL (1) | IL225904B (enExample) |
| RU (1) | RU2609412C2 (enExample) |
| TW (1) | TWI526209B (enExample) |
| WO (1) | WO2012096887A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3326617A1 (en) | 2004-06-12 | 2018-05-30 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
| UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
| PH12012500485A1 (en) | 2009-09-08 | 2012-10-22 | Signature Therapeutics Inc | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| US20110262359A1 (en) * | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US8569228B2 (en) | 2011-01-11 | 2013-10-29 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| EP2683394B1 (en) | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| CN105934257B (zh) | 2013-12-06 | 2020-10-09 | 韩捷 | 用于含氮和羟基的药物的生物可逆引入基团 |
| US11634384B2 (en) | 2014-11-25 | 2023-04-25 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| SG11201704178UA (en) | 2014-11-25 | 2017-06-29 | Kempharm Inc | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone |
| US9808452B2 (en) | 2015-10-01 | 2017-11-07 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| US10335406B2 (en) | 2015-10-01 | 2019-07-02 | Elysium Therapeutics, Inc. | Opioid compositions resistant to overdose and abuse |
| EP3210630A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| CN109562281B (zh) | 2016-05-25 | 2021-12-17 | 同心镇痛药物公司 | 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉 |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| US11541125B2 (en) | 2016-12-19 | 2023-01-03 | The Regents Of The University Of California | Noncrushable pill formulations |
| WO2018118902A1 (en) | 2016-12-19 | 2018-06-28 | The Regents Of The University Of California | Dual-enzyme responsive peptides |
| AU2018234911B2 (en) * | 2017-03-17 | 2024-04-18 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| AU2019310118A1 (en) | 2018-07-27 | 2021-03-11 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic TRPV1 agonists |
| WO2023055830A1 (en) | 2021-09-29 | 2023-04-06 | Ensysce Biosciences, Inc. | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU527371B2 (en) | 1980-09-16 | 1983-03-03 | Torii & Co., Ltd. | Amidine |
| US5109118A (en) | 1989-07-06 | 1992-04-28 | Yutaka Mizushima | Modified biologically active proteins |
| US5217987A (en) | 1989-10-30 | 1993-06-08 | Berger Stephen P | Dopamine uptake inhibitors in reducing substance abuse and/or craving |
| CA2032420A1 (en) | 1989-12-22 | 1991-06-23 | Akira Okuyama | Guanidinobenzene derivatives |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| EP0893437A4 (en) | 1996-04-10 | 2000-12-27 | Ono Pharmaceutical Co | GUANIDINO TRYPTASE INHIBITOR |
| JP2002529499A (ja) | 1998-11-13 | 2002-09-10 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
| US6586196B1 (en) | 1998-12-15 | 2003-07-01 | Tropix, Inc. | Multiple enzyme assays |
| US6849263B2 (en) | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
| AU3000800A (en) | 1999-02-18 | 2000-09-04 | Supergen, Inc. | Phosphocholine linked prodrug derivatives |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| EP2295043A1 (en) * | 1999-10-29 | 2011-03-16 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| ES2364452T3 (es) | 2001-06-11 | 2011-09-02 | Medarex, Inc. | Método para diseñar compuestos profármacos activados por cd10. |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| IL163667A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Novel sustained release pharmaceutical compounds to preventabuse of controlled substances |
| US20100092562A1 (en) | 2002-11-26 | 2010-04-15 | Hollenbeck R Gary | Sustained-release drug delivery compositions and methods |
| ATE454169T1 (de) | 2003-03-13 | 2010-01-15 | Controlled Chemicals Inc | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer |
| EP1782834A3 (en) * | 2003-03-13 | 2007-08-01 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower abuse potential and extended duration of action |
| ES2380622T5 (es) | 2003-05-29 | 2018-05-30 | Shire Llc | Compuestos de anfetamina resistentes al abuso |
| AU2004277400B2 (en) | 2003-09-30 | 2009-01-22 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
| CA2543142A1 (en) | 2003-10-24 | 2005-05-12 | Gilead Sciences, Inc. | Methods and compositions for identifying therapeutic compounds |
| EP1928881A2 (en) * | 2005-08-19 | 2008-06-11 | Pharmacofore, Inc. | Prodrugs of active agents |
| WO2007025249A2 (en) | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
| EP1934201A1 (en) | 2005-10-06 | 2008-06-25 | Auspex Pharmaceuticals Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| CN101365439B (zh) | 2005-12-05 | 2012-12-26 | 克塞诺波特公司 | 左旋多巴前体药物甲磺酸盐、其组合物及其用途 |
| EP2007762A2 (en) | 2006-04-10 | 2008-12-31 | Shire LLC | Mono and di-substituted oxycodone compounds and compositions |
| US20100144645A1 (en) | 2006-04-14 | 2010-06-10 | Shire Llc | Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse |
| EP2402037B8 (en) | 2006-05-26 | 2019-12-04 | Signature Therapeutics, Inc. | Controlled release of phenolic opioids |
| TWI401237B (zh) | 2006-07-24 | 2013-07-11 | ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備 | |
| EP2086986A4 (en) | 2006-09-14 | 2011-05-04 | Starfire Systems Inc | SYNTHETIC PROCESS FOR CYCLIC ORGANOSILANES |
| WO2008101187A2 (en) * | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | Pro-drugs of peripheral phenolic opioid antagonists |
| WO2008101202A1 (en) | 2007-02-16 | 2008-08-21 | Pharmacofore, Inc. | N-17-alkylated prodrugs of opioids |
| PL2596784T3 (pl) | 2007-11-23 | 2017-06-30 | Grünenthal GmbH | Kompozycje tapentadolu |
| US9023860B2 (en) | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
| WO2009080030A1 (en) | 2007-12-21 | 2009-07-02 | Lifecycle Pharma A/S | Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus |
| US20090192095A1 (en) | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
| EP2252150B1 (en) | 2008-02-14 | 2018-04-11 | Alkermes, Inc. | Selective opioid compounds |
| BRPI0908292B1 (pt) | 2008-05-05 | 2022-09-20 | Oramed Ltd | Métodos e composições para administração oral de exenatida |
| AU2009305563C1 (en) * | 2008-10-17 | 2015-09-03 | Signature Therapeutics, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
| US20100227921A1 (en) | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| EP2413937A1 (en) * | 2009-04-02 | 2012-02-08 | Shire LLC | Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof |
| BR112012001164A2 (pt) | 2009-07-17 | 2016-03-01 | Shire Llc | aminoácido de carbamato e pró-fármacos de peptídeo de opioides e usos dos mesmos |
| PH12012500485A1 (en) * | 2009-09-08 | 2012-10-22 | Signature Therapeutics Inc | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof |
| US20110262359A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| US9238020B2 (en) | 2010-04-21 | 2016-01-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug |
| US20130079364A1 (en) * | 2010-04-21 | 2013-03-28 | Signature Therapeutics, Inc. | Peripheral Opioid Agonists and Peripheral Opioid Antagonists |
| WO2011133150A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| EP2560489A4 (en) * | 2010-04-21 | 2014-01-22 | Signature Therapeutics Inc | COMPOSITIONS WITH ENZYMSPALTBAR OPIOID PRODRUGS AND HEMMER FOR THIS |
| US20110262360A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof |
| WO2012096886A1 (en) | 2011-01-11 | 2012-07-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| US8569228B2 (en) * | 2011-01-11 | 2013-10-29 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| EP2683394B1 (en) | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
-
2012
- 2012-01-09 US US13/346,062 patent/US8569228B2/en active Active
- 2012-01-09 CN CN201280003814.XA patent/CN103384472B/zh active Active
- 2012-01-09 DK DK12734573.4T patent/DK2663187T3/en active
- 2012-01-09 CA CA2814763A patent/CA2814763C/en active Active
- 2012-01-09 WO PCT/US2012/020649 patent/WO2012096887A2/en not_active Ceased
- 2012-01-09 EP EP12734573.4A patent/EP2663187B1/en active Active
- 2012-01-09 RU RU2013137452A patent/RU2609412C2/ru active
- 2012-01-09 JP JP2013548605A patent/JP6016810B2/ja active Active
- 2012-01-09 ES ES12734573.4T patent/ES2584634T3/es active Active
- 2012-01-09 AU AU2012205733A patent/AU2012205733B2/en active Active
- 2012-01-09 BR BR112013017296-7A patent/BR112013017296B1/pt active IP Right Grant
- 2012-01-10 TW TW101100923A patent/TWI526209B/zh active
-
2013
- 2013-04-23 IL IL225904A patent/IL225904B/en active IP Right Grant
- 2013-09-24 US US14/035,871 patent/US8962547B2/en active Active
-
2015
- 2015-01-09 US US14/593,855 patent/US9499581B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502972A5 (enExample) | ||
| JP2018172387A5 (enExample) | ||
| JP2019501133A5 (enExample) | ||
| JP5193230B2 (ja) | 歯肉隔離用の光重合材料 | |
| RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
| JP2016534063A5 (enExample) | ||
| JP2007523155A5 (enExample) | ||
| JP2011057693A5 (enExample) | ||
| JP2009537559A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2010509379A5 (enExample) | ||
| JP2009543860A5 (enExample) | ||
| JP2018524298A5 (enExample) | ||
| JP2013503862A5 (enExample) | ||
| NZ606548A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| RU2010141823A (ru) | Соединения и способ снижения мочевой кислоты | |
| JP2013510883A5 (enExample) | ||
| AR084801A1 (es) | Formulaciones inmunosupresoras | |
| JP2018502101A5 (enExample) | ||
| JP2011527345A5 (enExample) | ||
| JP2007507494A5 (enExample) | ||
| JP2009541387A5 (enExample) | ||
| JP2014504648A5 (enExample) | ||
| JP2011046708A5 (enExample) |